Can Calcium Be Removed From Arteries?

Removing calcium that has already deposited inside artery walls remains one of the hardest problems in cardiovascular medicine. No widely available drug or supplement reliably dissolves established arterial calcium in humans, though several interventional procedures can crack or shave it open, and a handful of experimental therapies have shown early promise in slowing or partially reversing it. The picture is more nuanced than a simple yes or no, because how the calcium got there, where it sits in the vessel wall, and how dense it has become all shape what can realistically be done about it.

Why Calcium Builds Up in Arteries in the First Place

Arterial calcification is not simply a passive buildup of mineral, the way limescale accumulates in a pipe. It is an active, cell-driven process. Smooth muscle cells in the vessel wall can shift their identity under stress, transforming into cells that resemble bone-forming osteoblasts and actively depositing calcium-phosphate crystals into the surrounding tissue.¹ Risk factors such as high blood pressure, diabetes, chronic kidney disease, and high phosphate levels accelerate this transformation.² In people with chronic kidney disease, elevated phosphate is a particularly strong driver, pushing smooth muscle cells toward an osteoblast-like state through specific signaling pathways.³

The body normally has built-in defenses against this. Proteins like matrix Gla protein (MGP), fetuin-A, and Gla-rich protein (GRP) act as calcification inhibitors by binding calcium and phosphate before crystals can grow. Under healthy conditions, smooth muscle cells release small vesicles loaded with these protective proteins. But under calcifying conditions, those vesicles lose their MGP and GRP content and instead become loaded with calcium, essentially turning from shields into seeds for further mineral deposition.⁴ When the balance tips, the protective brake fails and calcification accelerates.

Interventional Procedures That Physically Break Up Calcium

The most direct approach to dealing with heavily calcified arteries is mechanical. When a coronary or peripheral artery is so calcified that a standard balloon or stent cannot expand properly, cardiologists and vascular specialists have several tools to crack, grind, or pulverize the mineral deposits and restore blood flow.

The three main devices used today each work differently:

Rotational atherectomy: a tiny high-speed burr physically sands away the inner layer of calcium.
Orbital atherectomy: a spinning crown orbits the inside of the vessel, shaving calcified plaque.
Intravascular lithotripsy (IVL): a balloon-mounted device sends sonic pressure waves through the vessel wall, fracturing calcium deposits deep in the plaque without grinding the surface.

All three are used to prepare a calcified artery before placing a stent, and the choice depends on the location and severity of the calcium.⁵

Intravascular lithotripsy has gained particular attention in recent years. A meta-analysis found an overall procedural success rate around 94%, with meaningful widening of the vessel and low rates of serious complications.⁶ Because the sonic waves pass through soft tissue without damaging it, IVL can fracture both shallow and deep calcium deposits, which older mechanical tools sometimes miss.⁷ Atherectomy systems have also proven effective in leg arteries, where severe calcification of the upper-leg vessels can block blood flow. In that setting, atherectomy significantly increased vessel dimensions by removing surface calcium without raising the rate of major complications.⁸

These procedures are impressive at restoring blood flow, but they are treatments for the consequences of calcification, not cures for the underlying process. They crack calcium open so a stent can be placed; they do not strip the mineral out of the artery wall and leave behind a clean vessel. Calcification can and does return over time.

Can Drugs Dissolve or Slow Arterial Calcium?

The pharmacological side of the story is less settled and, frankly, more frustrating. Several approaches have been tried, but none has yet become standard practice for reversing established calcification in a general population.

EDTA Chelation Therapy

EDTA is a synthetic molecule that binds calcium and other metal ions, and it has been used in alternative medicine circles for decades with claims that intravenous infusions can “clean out” arteries. A systematic review of 24 studies in patients with existing cardiovascular disease found that 17 reported some improvement in outcomes after repeated EDTA infusions, while five found no significant effect and two found no benefit at all. The patients who seemed to benefit most were those with diabetes or severe blockages in leg arteries.⁹ The evidence is suggestive but far from conclusive, and mainstream cardiology guidelines do not recommend chelation for coronary artery disease. One persistent problem with systemic EDTA is that it grabs calcium from everywhere in the body, not just from artery walls, potentially weakening bones and stripping essential minerals.

Sodium Thiosulfate

Sodium thiosulfate (STS), originally used as a cyanide antidote and a treatment for certain skin conditions, has attracted interest for its ability to dissolve calcium salts. In dialysis patients, where calcification tends to be severe and fast-moving, a meta-analysis found that three to six months of intravenous STS was associated with a meaningful reduction in coronary artery calcium scores compared to usual care.¹⁰ However, when STS has been tested in calciphylaxis, a painful condition where calcium deposits damage the skin, a separate systematic review found no statistically significant improvement in skin lesions or survival.¹¹ So STS may help slow or modestly reduce coronary calcium in dialysis patients specifically, but it has not proven broadly effective for all forms of vascular calcification.

SNF472 (Hexasodium Fytate)

One of the more targeted experimental drugs is SNF472, an intravenous form of a natural compound called myo-inositol hexaphosphate. Rather than dissolving existing calcium, it works by blocking the growth of hydroxyapatite crystals, the specific mineral form that makes up vascular calcium deposits.¹² In a dose-response study of dialysis patients, the drug inhibited hydroxyapatite crystal formation by up to about 75% at higher doses.¹³ This is a “stop the growth” strategy rather than a “reverse the buildup” one, but preventing further calcification is valuable when the alternative is unchecked progression.

The Statin Paradox

If you have ever had a calcium score done while taking a statin, you may have been surprised to see a high number. One large observational study found that longer statin use was significantly associated with higher coronary calcium scores, with patients on statins for more than ten years showing roughly four and a half times the odds of severe calcification compared to those who had never used them, even after adjusting for other risk factors.¹⁴

This sounds alarming, but the story has a twist. Imaging research using CT scans tracked changes in plaque composition over time and found that while statins did not reduce total calcium volume, they shifted it toward a denser, more stable form. Softer, low-density calcium progressed less under statin therapy, while high-density calcium increased.¹⁵ Dense calcium is thought to be more stable and less likely to trigger a plaque rupture, which is the event that actually causes a heart attack. In other words, statins may make plaques “harder” in a way that is protective, even though the calcium score on a scan looks worse. This is one reason cardiologists have become cautious about interpreting calcium scores in isolation, especially in statin-treated patients.

What About Vitamins and Minerals?

The supplement world has seized on the idea that vitamin K2, vitamin D, and magnesium can reverse arterial calcification. The underlying biology is real but the clinical leap is large.

Vitamin K2 activates MGP, one of the body’s key calcification inhibitors. Vitamin D stimulates the production of MGP in the first place, so the two vitamins work in tandem: D makes the protein, K2 switches it on.¹⁶ This has led to a popular narrative that supplementing both vitamins can “decalcify” arteries. Clinical trials testing this hypothesis are underway, but no large completed trial has yet demonstrated that K2 and D3 supplementation reverses existing coronary calcium in humans. The biology is plausible; the proof is still missing.

Magnesium has a somewhat stronger observational track record. In the Framingham Heart Study, people in the highest tier of magnesium intake had about 58% lower odds of having any coronary artery calcification compared to those in the lowest tier.¹⁷ Lab and animal research suggests magnesium works through at least two mechanisms: it can physically interfere with the formation of hydroxyapatite crystals, and it can directly block the transformation of smooth muscle cells into bone-like cells.¹⁸ These findings are encouraging but remain observational and experimental. Having higher magnesium intake and having less calcification could both be markers of a generally healthier lifestyle rather than proof that magnesium directly prevents or removes calcium from arteries.

One point that gets overlooked in supplement discussions is that excess vitamin D itself can cause arterial calcification. An animal study showed that a toxic dose of vitamin D caused extensive calcium deposition in the aorta and multiple other arteries within days.¹⁹ The takeaway is not to avoid vitamin D, which is essential, but to be cautious about megadosing without medical guidance. More is not necessarily better when it comes to protecting your arteries.

The Role of Macrophages and Osteoclast-Like Cells

One reason researchers have not given up on the idea of biological reversal is that the body does have cells capable of dissolving mineralized tissue. In bone, osteoclasts break down calcium constantly as part of normal remodeling. Within atherosclerotic plaques, certain macrophages (a type of immune cell) can differentiate into osteoclast-like cells that resorb calcified deposits. Anti-inflammatory macrophages in particular appear to have protective properties and may help limit excessive calcification, while the balance between pro-inflammatory and anti-inflammatory macrophage populations in a plaque determines whether calcium keeps building or gets partially resorbed.²⁰

This has sparked interest in whether the immune environment around a plaque could be tilted to favor resorption. The same signaling system that controls bone turnover, involving a molecule called RANKL and its counterpart OPG, operates in the vascular wall and appears to link skeletal and vascular mineralization.²¹ Manipulating this system to encourage osteoclast-like activity in arteries without accidentally stripping calcium from bones is the challenge. So far, this remains a research direction rather than a therapy.

The Bone-Vascular Paradox

There is a frustrating clinical pattern that illustrates why treating arterial calcification is so tricky: people who lose calcium from their bones tend to gain it in their arteries, and vice versa. This inverse relationship between osteoporosis and vascular calcification has been documented extensively and appears to be driven by shared regulatory molecules that act in opposite directions on the two tissues.²² Chronic inflammation, aging, oxidized lipids, and changes in proteins like fetuin all contribute to a situation where the body seems to shuttle calcium from where it is needed (bones) to where it is harmful (arteries).²³

This paradox matters for treatment design. Any therapy that aggressively strips calcium from arteries risks worsening bone loss, and drugs that strengthen bones could theoretically worsen vascular calcification. Successful treatment probably needs to be tissue-specific, targeting the vascular side while leaving skeletal mineralization alone.

Targeted Nanoparticles and the Future of Reversal

The most exciting preclinical work on actual reversal of arterial calcification comes from nanoparticle research. Researchers designed albumin nanoparticles loaded with EDTA, the same chelating agent used in traditional chelation therapy, and coated them with antibodies that recognize degraded elastin, a protein found specifically at sites of vascular calcification but not in healthy arteries. When injected intravenously in rats with kidney-disease-induced arterial calcification, these targeted nanoparticles homed to the calcified sites and reversed mineral deposits. Four out of five treated aortas showed complete reversal of calcification, while untreated controls and rats receiving the same dose of untargeted EDTA showed no improvement at all.²⁴

Follow-up work confirmed these results using elemental calcium analysis and micro-CT imaging, showing that the targeted nanoparticles substantially reduced both the calcium content and the physical volume of calcified deposits in the aorta.²⁵ The key insight was that delivering EDTA systemically, without targeting, did nothing even at twenty times the dose contained in the nanoparticles. Only when the chelating agent was delivered precisely to calcified tissue did reversal occur.²⁴ This addresses the bone-vascular paradox directly: by confining the calcium-stripping action to diseased arteries, the treatment avoids the systemic mineral drain that makes untargeted chelation problematic.

These results are in animal models, and the leap from rat aortas to human coronary arteries is large. But the principle, that targeted delivery can achieve what systemic delivery cannot, represents a genuine shift in how researchers think about this problem.

Detecting Active Calcification Before It Becomes Dense

Standard CT scans detect calcium once it has already formed thick, macroscopic deposits. By then, the mineral is dense and difficult to reverse. A newer imaging approach uses a radioactive tracer called 18F-sodium fluoride in a PET scan to identify microcalcification, the earliest stage of mineral deposition that CT cannot see. In studies comparing the two techniques, regions of active microcalcification lit up on PET scans in areas where CT showed no calcium at all.²⁶

This matters for treatment because microcalcification represents the active front of the disease, the zone where smooth muscle cells are currently depositing mineral and where intervention might have the greatest impact. If therapies aimed at slowing or reversing calcification are going to work, detecting where calcification is actively growing, rather than just measuring what has already hardened, will be essential for targeting treatment and measuring whether it is working. It also offers a potential way to monitor high-risk patients, such as those on long-term dialysis, before calcium scores climb to severe levels.

Rare Genetic Conditions That Illuminate the Process

Some of the sharpest insights into arterial calcification come from rare genetic disorders where the process runs unchecked from birth. ENPP1 deficiency is one such condition. Without a functioning copy of the ENPP1 enzyme, which normally helps regulate mineralization, infants can develop widespread arterial calcification in their first weeks of life, often presenting with heart failure, respiratory distress, and high blood pressure. Among the 84 individuals analyzed in one characterization study, infant mortality reached 44%, and about 70% of survivors developed skeletal complications like rickets by age ten.²⁷

Studying these patients has helped researchers map the molecular brakes that normally keep calcification in check. The same enzymes and proteins that fail in genetic disorders operate more subtly in aging adults, where decades of inflammation, kidney decline, or diabetes gradually erode the system. Enzyme-replacement therapies developed for ENPP1 deficiency are being explored not just for those rare patients but as a way to understand whether restoring natural inhibitors could slow calcification in the broader population. The genetics, in other words, are a kind of accelerated preview of what happens in aging arteries, and the treatments being tested for the rare disease could eventually inform strategies for the common one.